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Neurodegeneration and neurodegenerative disorders have been a global health issue
affecting the aging population worldwide. Recent advances in stem cell biology have
changed the current face of neurodegenerative disease modeling, diagnosis, and
transplantation therapeutics. Stem cells also serve the purpose of a simple in-vitro tool for
screening therapeutic drugs and chemicals. We present the application of stem cells and
induced pluripotent stem cells (iPSCs) in the field of neurodegeneration and address the
issues of diagnosis, modeling, and therapeutic transplantation strategies for the most
prevalent neurodegenerative disorders. We have discussed the progress made in the
last decade and have largely focused on the various applications of stem cells in the
neurodegenerative research arena.
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INTRODUCTION
Progress in the field of clinical research andmedicine has decreased global mortality drastically. The
developed countries have extended the life span of their aging population. However, the modern
world is now faced with the issues of aging and age related disorders. Neurodegeneration and
neurodegenerative disorders are one of themajor health implications faced by the aging population.
Neurodegeneration studies have largely benefited from neuropathology and in-vivo research
(Agrawal and Biswas, 2015). Neurodegenerative disorders have been thoroughly investigated using
animal models, primary cultures, and post mortem human brain tissues (Marchetto et al., 2011).
Though informative, these approaches have some limitations. Data obtained from animal models
fails to directly correlate with that of humans because a rodent brain is not an exact mimic
of a human brain. Despite being highly conserved evolutionarily, mammalian genomes are not
identical. The embryonic development of mice and humans are considerably different and almost
20% genetic variability is accounted for (Strachan et al., 1997). Therefore species’ difference
prevents the animal data from successful validation during clinical field trials which poses a severe
economic burden. A study reported the failure of therapeutic drugs for treating amyotrophic lateral
sclerosis in human beings, which had earlier proved effective in case of rodents (Takahashi and
Yamanaka, 2013). Preclinical studies often do not efficiently translate to the clinic and the clinical
trial failures have been reported time and again (Prinz et al., 2011; Begley and Ellis, 2012). Primary
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culture of neurons is challenging because these are the post
mitotic differentiated cells which are difficult to sustain in the in-
vitro conditions. Ethical constraints have held back human based
research and thus the best possible source of human samples are
the postmortem brain tissues. However, these autopsied samples
depict the end stages of the disease and do not give much insight
into the intricacies of the disease’ developing stages (Marchetto
et al., 2011). Researchers are not willing to subject the human
beings to untested interventions, but the choices have been
limited so far.
Majority of neurodegenerative disorders have been incurable
(Alzheimer’s disease, Parkinson’s disease, Huntington’s disease,
Amyotrophic lateral sclerosis) so far but timely diagnosis can
help in the management and symptom alleviation. However,
researchers across the world are continuously striving to achieve
the cure and hope to achieve fruitful results in the near
future. Neurodegeneration studies are largely divided into two
major categories. One is the experimental modeling strategy
which allows for a comprehensive understanding of the disease
such as the etiology, pathophysiology, genotypic-phenotypic
interactions, symptomatic, and mechanistic insights. The second
is the medical approach which deals with the treatment, therapy,
and disease management. Stem cells and iPSCs find widespread
application for both, disease modeling as well as transplantation
and regenerative therapeutics. In the present review we shall
discuss the applicability of stem cell research in the field of
neurodegenerative disease modeling and provide the current
updates of how stem cell and induced pluripotent stem cell
based studies have been employed to address the diagnosis
and therapy of the most common neurodegenerative disorders.
We shall briefly touch upon the advances and preferable
methodologies employing stem cell and iPSC culture such as
the three dimensional (3D) culture which has revolutionized the
current trend of in-vitro studies. The article intends to highlight
the fact, that though animal based in-vivo research is absolutely
necessary for the neuroscience research, one cannot wholly and
solely depend upon it and human based stem cell driven research
has and will open newer avenues for the neurodegenerative
disorders′ modeling and treatment.
STEM CELLS AND INDUCED
PLURIPOTENT STEM CELLS (IPSCS) IN
NEURODEGENERATION: WHY THE
CHOICE?
It is easier to say that cells of human origin can be directly
employed to generate a clearer picture of the neurodegenerative
diseases but practically the approach is not as simple as it
seems. The in-vitro scenario is devoid of an intact organ
system, organ-organ interactions are missing and the blood
supply and connective tissues are lacking. Every disease has
its characteristic cellular, molecular, anatomical, genotypic, and
phenotypic attributes. If one has to model these various aspects
in-vitro, very specific cell types expressing the disease phenotypes
are required. Sustaining the culture of such specific cells is
another challenging task that requires standardized protocols,
select growth conditions, and expertise. For example, Parkinson’s
disease requires the culture of dopaminergic neurons, ALS
requires the culture of glial cells, motor neurons, and astrocytes
and Huntington’s disease requires the culture of medium spiny
and striatal projection neurons as discussed in the later sections.
All these requirements have been largely met by the use of stem
cell technology.
Stem cells in brief are the naïve cells of the body with an
exceptional ability to self-renew, proliferate, differentiate, and get
programmed for multi-lineage commitment (Cananzi and De
Coppi, 2012; Liu et al., 2013; Kumar et al., 2015). Their origin can
either be fetal, embryonic, or adult tissues of the body (Nam et al.,
2015; Singh et al., 2015). Despite a few ethical concerns stem cell
biology is finding widespread applicability in the field of research
and medicine. Stem cells can be practically converted into any
possible cell type and thus are being routinely used to model
diseases. Monogenic disorders with a clear cut cellular phenotype
and high penetrance are comparatively easier to model than the
late onset diseases involving a number of genes and showing
less penetrance. In case of the monogenic disorders the disease
associated gene is deliberately mutated via gene editing to obtain
the stem cell models. Embryonic stem cells (ESCs) harboring
the chromosomal aberrations are used for the modeling of the
chromosomal diseases. The late onset complex diseases which
cannot be prenatally diagnosed aremodeled using patient derived
iPSCs more effectively (Avior et al., 2016).
In-vivo animal models have so far been used to experimentally
model diseases however, the data generated fails to recapitulate
the human diseases and thus cannot be directly extrapolated
(Yamanaka, 2009). This forms a major limitation of the various
animal based studies. Only samples of human origin can be
employed to overcome this major hurdle. Neurodegeneration
leads to a gradual loss of brain functionality via an irreversible
gradual loss of neurons and other cells of the central nervous
system (Peng and Zeng, 2011). In this regard transplantation
therapy is employed to restore and repair the damaged circuitry
of the brain as well as to replenish the lost neuronal population
(Thompson and Björklund, 2015). Successful commitment of
stem cells toward the neuronal lineage is widely reported
and myriad of protocols are available to achieve the same
(Nikoletopoulou and Tavernarakis, 2012; Ferroni et al., 2013; Lu
et al., 2015).
Diseases such as brain ischemia (Ju et al., 2014), spinal
muscular atrophy (Frattini et al., 2015), spinal cord injury
(Lukovic et al., 2015), amyotrophic lateral sclerosis (Nicaise
et al., 2015), Machado-Joseph disease (Mendonça et al., 2015),
and many more have been studied and stem cell therapy has
been effectively employed for the same. Embryonic stem cells are
pluripotent in nature and hold an excellent potential for restoring
brain injuries and neurodegeneration via transplantation
therapy, however tumor formation restricts their widespread
application (Aleynik et al., 2014). Mesenchymal stem cells
which are multipotent also find widespread application because
they are immunomodulating in nature. Immunomodulation
simply refers to the unique ability to escape the host’s immune
system surveillance thereby leading to successful transplants
without eliciting an adverse immune response (Glenn and
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Whartenby, 2014). Neural progenitor cells or NSCs isolated from
fetal brain are again multipotent in nature and are stringently
committed toward the neuronal lineage. They are suitable
because of a reduced risk of tumor formation however they
are difficult to procure and usually few in number (Jiang et al.,
2012). Apart from naïve stem cells, iPSCs derived via a reverse
programming of somatic cells finds widespread application now
a days (Takahashi and Yamanaka, 2006). Induced pluripotent
stem cells are being produced in bulk and various iPSC cell
lines are commercially made available. The use of Parp1 i.e.,
poly(ADP-ribose) polymerase 1 for the production of iPSCs is
now well reported and this has also reduced the tumor forming
risk sufficiently (Chiou et al., 2013). However, the formation of
teratomas has not been completely eliminated. Production of
iPSCs is well reported from various somatic cells of the body
such as the peripheral blood cells, hepatocytes, stomach cells
(Okano et al., 2013), and keratinocytes (Aasen et al., 2008). It
is now well reported that just 10µl of capillary blood drawn
from finger tips can be used to generate iPSCs (Tan et al., 2014).
Patient derived induced pluripotent stem cells are widely used
cells of human origin which can directly be used to model
the various human neurodegenerative diseases (Sterneckert
et al., 2014). Scientific groups have reported disease specific
iPSCs cell lines (Dimos et al., 2008). Stem cells and induced
pluripotent stem cells have been widely used for modeling several
neurodegenerative diseases as well as used in transplantation
therapy. Spinal muscular atrophy has been efficiently modeled
in-vitro using patient derived iPSCs (Sareen et al., 2012; Wang
et al., 2013). The first of their kind, these iPSCs derived models
efficiently depicted the disease phenotypes. However, iPSCs
too have a few limitations. Neurodegenerative disorders are
generally the late-onset diseases and symptoms begin to manifest
with increasing age. Thus modeling such diseases via the animal
models is not only time consuming but also cost heavy. It
is generally assumed and even reported that patient derived
iPSCs harbor the disease mutations and carry the epigenetic
background of the patient, thus making them an excellent choice
as the in–vitro disease models. However, when somatic cells
are reprogrammed to an induced pluripotent state they lose
the age associated features, undergo rejuvenation, and their
embryonic age is reestablished. It is well reported that even
aged donor derived iPSCs are rejuvenated and age reversal is
evident as there is a loss/decrease in the markers of senescence,
enhanced mitochondrial fitness, and an increased telomere
length (Lapasset et al., 2011; Freije and López-Otín, 2012). Thus
even these patient derived iPSCs do not effectively model the
late onset neurodegenerative diseases as they lack the age related
phenotypes. However, this hurdle has been largely overcome
by progerin induced aging in the iPSCs (Miller et al., 2013).
Progerin is a truncated transcript of lamin A (nuclear envelop
protein) formed by mutation in the gene LMNA. Accumulation
of progerin in the nuclear membrane results in the dysfunction
of lamin A resulting in interrupted chromatin organization,
cell cycle, telomere maintenance, and DNA damage response.
High progerin levels are associated with aging. Age related
phenotypes have been observed in the progerin exposed iPSCs
such as degeneration of dendrites, neuromelanin accumulation,
AKT deregulation, mitochondrial swelling, and reduction in the
TH-positive neurons (Miller et al., 2013). These iPSCs harboring
the aging markers will thereby mimic the neurodegenerative
disorders more efficiently. In the upcoming sections we shall
discuss the application of stem cells and iPSCs for the most
common and globally prevalent neurodegenerative disorders.
Figure 1 shows a diagrammatic representation of progress made
in the field of stem cell research in context with neuroscience.
ALZHEIMER’S DISEASE (AD)
Alzheimer’s disease (AD) is described as “Presenile dementia”
by German psychiatrist Alois Alzheimer and is one of the most
prevalent neurodegenerative disorders of the world. It is a leading
cause of dementia in the aging population and has lately been
declared the sixth major reason for death. Patients having AD
are reflected with cognitive deficits, memory loss, and behavioral
changes and these changes are inherently associated with
neurodegeneration (Blundell and Shah, 2015). Hippocampus,
amygdala, neocortex, and basal forebrain regions of the brain
are adversely affected leading to the severe impairment of
cognition and memory. Neurofibrillary tangles (NFT) and β-
amyloid plaques are the pathological hallmarks of AD (Peng
and Zeng, 2011). Hyperphosphorylation of tau proteins and
amyloid peptide aggregates are responsible for the formation
of NFT and β-amyloid plaques respectively. Alzheimer genetics
involves the mutated forms of presenilin 1 (PSEN1), presenilin 2
(PSEN2), Amyloid Precursor Protein (APP), and apolipoprotein
E. There are still no permanent treatments available for AD
except acetylcholinesterase (AChE) inhibitors which provide
only temporary relief (Birks, 2006; Lindvall and Kokaia, 2006).
Several drugs serve as potent acetylcholinesterase inhibitors
such as tacrine, tacrine derivatives, donepizel, rivastigmine,
galantamine, and the glutamate receptor agonist memantine
(Romero et al., 2013; Cecilia Rodrigues Simoes et al., 2014; Ehret
and Chamberlin, 2015). These FDA approved pharmacological
interventions provide only symptomatic relief for a limited
period and may also have side effects in the long run. Removal
of the Amyloid β levels from the brain is considered an effective
therapy for AD and physiologically, the enzyme neprilysin has
been reported to be involved in the clearance of the Amyloid β
plaques by degrading it (Iwata et al., 2001). Other proteinases
such as cathepsin B (Mueller-Steiner et al., 2006) and plasmin
(Melchor et al., 2003) too have a similar role and are used to
decrease the levels of Aβ thus acting as potent therapeutic agents
for AD. A number of past studies show the relevance of nerve
growth factor (NGF) in the prevention of neurodegeneration and
amyloid toxicity (Tuszynski et al., 2005; Tuszynski, 2007) but a
severe limitation with NGF is that it is unable to cross the blood
brain barrier and therefore cannot be delivered peripherally.
Transgenic animal models of AD carrying the disease
mutations have given ample insight into the etiology and
pathophysiology of the disease but have failed to entirely
recapitulate the formation of NFT and β-amyloid plaques
together. Human disease pathophysiology has not been
completely depicted by mouse models so far (D’avanzo et al.,
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FIGURE 1 | Diagrammatic representation of progress made in the field of stem cell research in context with neuroscience.
2015; Pistollato et al., 2015) and clinical failure of drugs has
also been reported (Cavanaugh et al., 2014; Langley, 2014).
Past studies demonstrate that the implantation of genetically
modified fibroblast cells into the forebrain of the patients led to
decreased neurodegeneration and restored the cognitive deficits
associated with AD (Tuszynski et al., 1994). However, fibroblasts
are immobile in nature and cannot migrate efficiently within the
different brain regions, but on the other hand transplanted stem
cells can effectively migrate and release growth factors to the
damaged sites. Thus, positional stem cell transplantation therapy
may prove more fruitful in this regard (Flax et al., 1998).
Many published studies report the successful use of stem cell
transplantation strategies that have helped in the management
of AD. One study showed that ESCs derived neural stem cells
(NSCs) when transplanted into the mouse model of AD served
as a better tool for the treatment for AD in comparison to using
ESCs alone. The transplanted NSCs were stable, successfully
differentiated into the cholinergic neurons and memory was
found to be increased. On the other hand the vehicle group which
received ESCs alone developed teratomas (Wang et al., 2006).
Another study was carried out on the mouse brain that expressed
aggregates of plaques and tangles. Genetically modified NSCs
for expression of BDNF were successfully transplanted into the
rodent brain which led to improved learning and memory. These
NSCs did not decrease the level of the amyloid plaques instead
the increased levels of BDNF helped in the formation a number
of new synapses (Blurton-Jones et al., 2009).
Stem cells and iPSCs have been extensively employed to study
the human specific responses and unravel the complexities of
AD. In 2011, Yagi et al. first derived neurons from patient iPSCs
which carried mutant (PSEN2) and (PSEN1) (Yagi et al., 2011).
Since then a number of studies have been dedicated toward this
approach of patient specific iPSC derived AD modeling. The
catalytic subunit of the enzyme gamma-secretase is encoded by
the gene (PSEN1) and mutated form of this gene results in the
manifestation of the early stages of FAD (familial Alzheimer’s
disease). Stem cells models of the disease have largely targeted
the involvement of gamma-secretase activity in the elucidation of
sporadic as well as familial AD. For example, studies report that
the Aβ42/40 ratios were higher in neurons derived from patient
iPSCs (derived from PSEN1 mutant fibroblasts) in comparison
to the healthy controls (Livesey, 2014). Similarly mutations in
APP have also led to a similar increase in the Aβ42/40 ratios in
the neurons of the human forebrain. A couple of studies have
modeled FAD using iPSCs carrying mutations in the APP, such as
dominant V717L and recessive E9631 bearing mutation (Kondo
et al., 2013) and the V717I mutation bearing iPSCs (Muratore
et al., 2014). A study carried by Israel et al. demonstrated that
inhibition of gamma or β-secretase activity led to a decreased
production of Aβ40, however γ-secretase inhibition did not
prevent phosporylation of tau proteins (Israel et al., 2012).
Stem cell derived neurons and astrocytes have been widely
used to model FAD in-vitro. Gene mutations bring about
observable changes in the cellular phenotype such as the Aβ
peptide changes. However, how APP processing is interlinked
with tau phosphorylation is an aspect which has not been
efficiently modeled so far. The onset and initiation of AD is
largely attributed to the amyloid hypothesis. APP is a single
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pass transmembrane protein and its proteolytic cleavage forms
short Aβ peptides (Livesey, 2014). Mutation in the genes that are
involved in the proteolysis of APP play a pivotal role in FAD.
Aβ42 is the longer form of amino acid and its accumulation
brings about neurodegeneration and cell death (Sproul et al.,
2014). Post translational and cellular localization changes in the
microtubule-associated tau protein play the second biggest role
in AD progression. Tau changes and amyloid plaques if modeled
together via stem cells will provide the best models of AD (Moore
et al., 2015). Simple monogenic iPSCs’ derived neurons are not
sufficient to model amyloidosis since they accumulate low levels
of toxic β-amyloid plaques. To overcome this hurdle stem cell
lines bearing multiple mutations have been generated, which also
over express the mutated genes such as APP and PSEN1.
PARKINSON’S DISEASE (PD)
Parkinson’s disease ranks second after AD in being the most
common and widely prevalent neurodegenerative disorder
inflicting almost one percent of the aging population globally.
Dopaminergic neuron loss from the nigrostriatum and substantia
nigra pars compacta brain regions is the major characteristic of
the disease (Marchetto et al., 2010). The other major hallmark
being the presence of lewy bodies (α-synuclein aggregates)
(Spillantini et al., 1998) which further promotes neuronal
death due to the altered firing pattern of the neurons (Janezic
et al., 2013). The genetic involvement of ubiquitin carboxy
terminal hydrolase L1, serine threonine kinase 1, parkin, DJ-1,
α-synuclein, and leucine-rich repeat kinase 2 have been reported
in the case of genetically acquired familial PD (Dauer and
Przedborski, 2003). Environmental influence in conjunction with
age, genetic polymorphisms and chemical exposure predispose
an individual toward sporadic PD, however the complex etiology
is yet to be fully understood (Adami et al., 2014). Fitzmaurice
et al. showed that variation in Aldehyde dehydrogenase
enhances the pesticide effect related to PD thereby proving that
environmental influences work in conjunction with genetics
(Fitzmaurice et al., 2014).
Rigidity, resting tremor and bradykinesia are the major
symptoms which make PD the most common movement
disorder of the world affecting individuals post 65 years of age
(Fu et al., 2015). Mechanistic and pathophysiological studies have
given us a deep understanding of the disease. PD is generally
associated with a disrupted calcium homeostasis, inflammation,
disrupted kinase pathways, generation of reactive oxygen species,
and dysfunctional mitochondria (Schapira et al., 2014; Xiao
et al., 2016). Animal and cellular models have given us a
deep understanding of the disease but data generated is not
fully applicable to human subjects due to difference in disease
pathogenesis of animals and humans (Devine et al., 2011).
PD so far has been managed using monoamine oxidase
inhibitors, dopamine agonists, levodopa, and deep brain
stimulation (Politis and Lindvall, 2012). The latter employs
stimulation of the ventral intermediate nucleus, a part of the
thalamus which can greatly reduce the symptoms of tremor.
Other symptoms like rigidity and bradykinesia are also alleviated
after the stimulation of the subthalamic nucleus or internal
segment of globus pallldius. However, these treatments fail
to repair the damaged brain region and the oral drugs are
not effective beyond 5 years. Administration of L-DOPA (L-
dihydroxy-phenyl alanine) can induce dyskinesis and fails to halt
the disease progression (Politis and Lindvall, 2012).
The earliest transplantation studies employed the use of
fetal ventral mesencephalic tissue of human origin (hfVM)
which were engrafted in the striatum of the PD patients and
laid the basis for cell therapy for PD. The attempts were
successful and symptomatic relief was provided for almost 16
years in the successful cases. However, the clinical trials produced
anomalies and the success of the approach was further challenged
by the presence of side effects such as GIDs (graft induced
dyskinesis). The reason was the presence of the serotonergic
neuroblasts in the hfVM that led to an imbalanced serotonin/DA
transporter ratios and false DA release (Politis and Lindvall,
2012). Studies also indicated that the survival of the transplanted
fetal mesenchymal cells was very low and ethical issues further
blurred the scope of this therapy. Since PD is characterized by
a regional loss of dopaminergic neurons, transplantation, and
replenishment therapy employing stem cell and iPSC derived
dopaminergic neurons (yielding a pure population) in the SN
region provides an excellent alternative.
Neurons with the DA phenotype have been developed from
ESCs by using sonic hedgehog (Shh) and fibroblast growth factor-
8 (FGF8) or the over expression of Nurr1 by using genetically
modified NSCs (Kim et al., 2003). Co-culture of mouse bone
marrow stromal and monkey ESCs have successfully yielded
dopaminergic neurons in the past (Takagi et al., 2005). Studies
further demonstrate the successful intrastriatal transplantation of
fetal brain human NSCs in the MPTP lesioned monkeys which
brought about improved behavioral changes (Redmond et al.,
2007). A study reported that when NSCs were isolated from
the patient brain, converted into dopaminergic neurons and re-
implanted into the patient brain, the symptoms of trembling and
rigidity were substantially reduced. The brain scans revealed an
increase in the dopamine production by almost 58% and even
when the levels did not increase further the symptoms did not
revert back, hinting at a possible restorative potential of stem cell
derived dopaminergic neurons (Hassan et al., 2010).
Transition from pluripotent stem cells to iPSCs has shown
promising results and has opened new avenues for the modeling
of PD. Dopaminergic neurons derived from patient specific
iPSCs were successfully transplanted into a Parkinsonian rat
striatum and showed a considerable reduction in motor
asymmetry (Hargus et al., 2010).The role of mitophagy has been
strongly implicated in PD. The mitochondrion targeted kinase
PINK1 accumulates on the outer membrane of mitochondria on
depolarization and further recruits Parkin which is instrumental
in initiating mitophagy (Van Laar et al., 2010; Cai et al., 2012).
The data generated on animal models so far has generated
conflicts regarding the direct involvement of mitophagy in PD.
However, PINK1 mutated dopaminergic neurons from human
patient derived iPSCs have given us a clearer understanding of the
mitophagy theory, thus proving once again that stem cell derived
human diseasemodels are far superior and farmore edifying than
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any animal model (Seibler et al., 2011). It is also implicated that
mitophagy may be a result of aging and may not have a direct
correlation with the disease; however the hypothesis is still under
contradiction. Progerin expression and long term culture have
been employed to produce artificial aging of neurons in culture.
These aged neurons have been treated as a model to study the late
onset of PD and to elucidate the disease phenotypes (Miller et al.,
2013).
As mentioned earlier, apart from disease modeling, stem
cells, and iPSCs hold great promise as the in-vitro screening
tools for therapeutic agents, drugs, and compounds. It has been
reported that rapamycin, GW5074 (LRRK2 kinase inhibitor) and
coenzyme Q10 diminish the cytotoxic effect of concanamycin A
also known as valinomycin in patient derived iPSC neurons. It
has been clearly seen that GW5074 does not reduce oxidative
stress in the healthy neurons from control subjects whereas
effectively lowers oxidative stress in the patient derived neurons
bearing mutated PINK1 (Cooper et al., 2012). This difference
underlines the importance of therapeutic compound screening in
diseasemutation bearing cells as well as the healthy cells. Another
example where stem cells have been employed to study the
PD physiology is the mutation correction of A53T α-synuclein
via genome editing which diminished the formation of lewy
bodies in iPSC derived dopaminergic neurons (Ryan et al., 2013).
Mutation bearing iPSCs will thus serve as an excellent tool for
screening and assessing the biosafety of drugs and compounds
as well as identifying the underlying signaling cascades and
novel therapeutic targets. The generation and characterization
of iPSCs is cumbersome and the differentiated population of
dopaminergic neurons may contain traces of the undifferentiated
cells which may lead to teratoma formation. Thus, if patient
derived fibroblasts are directly converted to dopaminergic
neurons, the limitations with iPSCs can be overcome (Han et al.,
2015). The successful differentiation of fibroblasts into the DA
neurons are reported in literature and has paved way for potential
disease modeling (Caiazzo et al., 2011; Kim et al., 2014). The stem
cell technology can be used to identify the biochemical markers
of the disease and can thus help in the diagnosis of early PD (Xiao
et al., 2016).
AMYOTROPHIC LATERAL SCLEROSIS
(ALS)
A fatal neurodegenerative disease ALS is caused due to the
motor neuron degeneration in the spinal cord, brain stem,
and the primary motor cortex (Thomsen et al., 2014) which
results in muscle wasting, paralysis and eventually death due
to respiratory failure (Hedges et al., 2016). First described by
Charcot in 1874, ALS is also known as Lou Gehrig’s disease
(Marchetto et al., 2010). ALS has been linked with FTD
(frontotemporal lobar dementia) due to symptomatic, clinical,
genetic, and pathological overlap. ALS and FTD when occur
together further shorten the life span of a patient further. The
two diseases are often considered the two ends of the same
disease spectrum. Ling et al. gave evidence at the genetic level
by reporting that FTD-ALS and ALS patients carry similar
mutated genes (Lee and Huang, 2015). Many gene mutations
are responsible for causing familial ALS such as mutations in
PFN1, FUS/TLS (fused in sarcoma/translocation in liposarcoma),
TARDBP or TDP-43 (TAR-DNA-binding protein 43), UBQLN2,
C9ORF72, SOD1 (superoxide dismutase 1), HNRNPA1, OPTN,
and VCP (Adami et al., 2014). Recently a new gene named
TBK1 has been discovered which plays a crucial role in
inflammation & autophagy which are inherently associated
with ALS pathogenesis (Cirulli et al., 2015). Pathogenesis
of sporadic ALS is attributed to glutamate excitotoxicity,
protein mitochondrial dysfunction, aggregation, oxidative stress,
deficiency of neurotrophic factors, glial cell dysfunction, and
impaired axonal transport, all of these together eventually lead
to the accumulation of intracellular neurofilaments (Kiernan
et al., 2011; Robberecht and Philips, 2013). Riluzole is the
only therapeutic drug commercially available which helps in
the disease management, but its effect does not last beyond 6
months (Cetin et al., 2015). ALS has been widely studied using
animal models; however reported failure of clinical trials has
somehow restricted the sole dependency on in-vivo research
(Gordon and Meininger, 2011). Patient specific iPSC banks hold
promise for personalized medicine and are a good alternative for
screening the efficacy of a number of drugs and compounds for
the treatment of ALS (Giri and Bader, 2015).
Transplantation therapy employing stem cells can be
effectively used as a therapeutic measure to deal with the
devastating disease. Mesenchymal stem cells and hematopoietic
stem cells have been efficiently employed as transplants
in the affected spinal cord and have favorably supported
ALS management (Mazzini et al., 2012). However, studies
were conducted on a small group of patients and thus
thorough research continues so as to be applicable for a
larger pool of patients. Neural stem cells (NSCs) ESCs, glial-
restricted progenitor cells (GRPs), and induced pluripotent
stem cells (iPSCs) also offer a potential alternative for
transplantation approaches and can be used (Traub et al.,
2011). It is hypothesized that when donor cells are engrafted
near the damaged motor neurons, they not only have an
immunomodulatory effect but secrete trophic factors which
improves the overall therapeutic potential of the transplant. Such
transplants can effectively delay the progression and even the
initiation of the disease (Teng et al., 2012).
The direct or peripheral injection of MSCs into the spinal
cord of patients serves as a potent treatment for ALS and several
studies have reported the therapeutic potential of MSCs (Mao
et al., 2015). Several studies report the beneficial aspects of
transplantable MSCs, which are used to deliver the required
neurotrophic factors aiding in the prevention of motor neuron
loss, improve survival of experimental animals, and delay the
disease progression (Zhao et al., 2007; Vercelli et al., 2008;
Uccelli et al., 2012; Krakora et al., 2013). Genetically manipulated
MSCs which secrete GDNF (glial-derived neurotrophic factor)
have been reported to increase the life of ALS rats by rescuing
motor neuron loss (Suzuki et al., 2008). “NurOwn” developed by
BrainStorm Cell Therapeutics are specialized MSCs which can
secrete neurotrophic factors, can successfully differentiate into
neuronal cells and can be used for ALS treatment. The cells are
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under the clinical trial phase (Therapeutics, 2015). A number of
clinical trials have been conducted to assess the efficacy and safety
of MSCs and many are still in process.
Neural stem cells have a specific lineage commitment for
the cells of the CNS and find widespread applicability in the
neurodegenerative disorders. When engrafted in the animal
models of ALS, NSCs have been reported to exert a protective
effect on the adjacent motor neurons (Hefferan et al., 2012). Stem
cells not only provide symptomatic relief but help in restoration
of the brain damage via repair and neurogenesis which is
triggered in the affected spinal cord. Successful transplantation
of neural stem cells from aborted fetuses into the patient’s spinal
cord has been reported (Xu et al., 2012). Results of the phase
I clinical trials have been documented and show that stem cell
therapy is a reasonably safe and can be used to treat a large
enough pool of patients (Mazzini et al., 2015).
The familial cases of ALS can be modeled by ESCs harboring
the disease mutations but the sporadic cases require the use of
patient specific iPSCs. Literature reports the use of iPSCs for
ALS modeling and hints at a possibility that motor neurons
derived from patient specific iPSCs can be employed for the
recapitulation of disease phenotypes. ALS exhibits a complex
physiology and thus requires use of more than one cell type
for its modeling. It was shown that SOD1 bearing astrocytes
(from ESCs) exerted toxicity on the adjacent motor neurons
(Wada et al., 2012) whereas iPSCs derived astrocyte bearing
the TDP-43 mutation exerted no toxicity (Serio et al., 2013),
hinting at the relevance of the co-culture of cells for modeling the
complex disease. One drawback with in-vitro disease modeling of
ALS is the short survival duration of motor neurons in culture
which limits the study of phenotypic signs occurring in the
aged diseased tissues. However, if iPSC derived motor neurons
are grafted in the animal model it will increase the survival of
these cells. The grafted cells can be recovered lately to visualize
the disease phenotypes in the post mortem rodent tissues, thus
offering a possible solution (Coatti et al., 2015).
Studies report that iPSC derived glial rich population of neural
progenitors can be successfully transplanted into the spinal cord
of mice suffering from ALS. These transplanted cells show a good
survival, differentiation potential, and also enhanced the life span
of the treated animals (Kondo et al., 2014). Stem cell therapy has
been an area of debate for a long time. The beneficial aspects
cannot be overlooked, but extensive clinical trials are in progress
so as to generate an effective treatment and possible cure for ALS
in the near future.
HUNTINGTON’S DISEASE (HD)
Huntington’s disease is a fatal genetic neurodegenerative disorder
with no cure so far. Genetically acquired in an autosomal
dominant manner, the disease is caused by an increased
trinucleotide CAG (encoding polyglutamine) repeat in the ITI5
huntington gene. The CAG repeats are normally less than 36
in a healthy individual however a repeat of more than 40
will predispose an individual toward the disease. The striatum,
cortex, substantia nigra pars compacta, substantia nigra pars
reticulata, globus pallidus are the major brain regions which
are subjected to severe degeneration (Carter and Chan, 2012).
Enkephalin and gamma-aminobutyric acid containing medium
spiny neurons, glutaminergic, GABAergic, and parvalbuminergic
striatal projection neurons are severely affected. Mutated
Huntington protein forms aggregates in the nuclei and cytoplasm
of the brain tissues. Being a Cognitive, movement, psychiatric
disorder the disease brings about mitochondrial, synaptic, and
axonal transport dysfunction. The disease leads to a severe
transcriptional dysregulation, proteolysis, and excitotoxicity
(Peng and Zeng, 2011).
The disease, though incurable can be managed via gene
therapy and drugs to alleviate symptoms. Drugs provide
temporary symptomatic relief and largely target the motor
aspects of HD. Tetrabenazine is dopamine depleting in nature
and is used to reduce chorea, however severe side effects restricts
its widespread use as a drug of choice for HD (Frank, 2014).
The pros and cons of the various animal models of HD have
been reviewed by Pouladi et al. In 2013 (Pouladi et al., 2013).
HD has been widely modeled via rodent models in-vivo, however
here too the success of the clinical trials has been limited. The
problem lies not only with the animal model chosen but also with
the robustness of the preclinical studies (Menalled and Brunner,
2014).
Gene therapy employs RNAi mediated silencing and
reduction in the mutated HTT protein translation. However,
gene therapy is effective only at the earliest stage of the disease
but the symptoms are not visible until the later stages by
which the major damage is already done. Replenishing the
stratial neuron population by intracranial transplantation is
an alternative cell therapy approach. Fetal striatal tissue grafts
have been employed in the non human primate and rodent HD
models as a means of transplantation therapy (Chen et al., 2014).
These grafted tissues have a low survival rate and since they
are procured from aborted fetuses, ethical constraints are high.
Limited availability of donors further restricts the scope of this
promising strategy. Neural progenitor cells (NPCs) derived from
stem cells and iPSCs are a good alternative in this regard.
Successful differentiation of human ESCs into the GABAergic
and DARPP32 positive medium spiny neurons (MSNs) is well
reported. NPCs transplanted into the chemical lesion mouse
model of HD showed efficient connectivity with the host neurons
and also alleviated motor deficits (Ma et al., 2012). Another
study by Carri et al. reports the successful differentiation of
ESCs and iPSCs into MSNs carrying adenosine and dopamine
receptors (Carri et al., 2013). However, NPCs transplantation
has been more successful in chemical lesion HD mouse models
as compared to the transgenic (R6/2) mouse model, the reason
speculated being the short life span of the transgenic mouse
(El-Akabawy et al., 2012). Along with disease modeling and
regenerative transplantation therapy, stem cells and iPSCs can
be simply used as an in-vitro tool for screening the efficacy and
biosafety of drugs and small molecule compounds that help in
relieving the symptoms of the disease as well as bring about a
reduction in neurodegeneration (Carter and Chan, 2012). HD
patient specific cell lines have been generated which recapitulate
the disease specific phenotypes more closely (Consortium, 2012).
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The gene therapy for HD involves targeting the mutant
HTT allele (mHTT) transcript by RNA interference and ASOs
(antisense oligodeoxynucleotides) specifically without disturbing
the normal HTT allele transcript (Carroll et al., 2011; Hu et al.,
2012). The exact role HTT in normal conditions is still not clearly
understood but a study reports that HTT knockout mice do not
survive and are lethal embryonically. Thus targeting only the
mutant allele is preferable. ASOs target complimentary mRNA
via RNase Hmediated degradation and are important in research
as they are capable of targeting the SNPs (single nucleotide
polymorphisms). These SNPs are responsible for the difference
between normal and mutated HTT gene alleles (Carroll et al.,
2011). Studies have been carried out in the non human primate
and rodent models of HD and disease alleviation was observed
(Kordasiewicz et al., 2012). This paves way for a possibility
that patient derived iPSCs carrying the disease mutations can
be effectively corrected via ASOs and gene silencing and the
NPCs thus derived can be successfully transplanted. Thus stem
cell therapy in amalgamation with gene therapy can help in the
management of the incurable disease in future (Chen et al., 2014).
THREE DIMENSIONAL (3D) STEM CELL
BASED STUDIES: APPLICATION IN
NEURODEGENERATION AND
NEURODEGENERATIVE DISORDERS
In-vitro stem cell based studies are the best possible alternative
to animal models because cells of human origin are used
and thus data generated can be easily extrapolated to human
subjects. However, two dimensional in-vitro studies have many
limitations. The 2D culture comprise a homogenous population
of cells, complex intercellular interactions are lacking, the
cultures do not represent the complex microenvironment of
an organ like the brain and the intact organ physiology is
lacking. In this regard 3D cultures have played a pivotal role
in overcoming the hurdles of typical 2D studies and also find
widespread application in the field of neuroscience. Advances
have been made to recapitulate the brain development and
literature supports successful formation of stem cell derived 3D
cortical and cerebral organoids (Lancaster et al., 2013; Sasai, 2013;
Lancaster and Knoblich, 2014).
AD has been extensively modeled using stem cell and iPSC
derived 2D neuronal cell culture however, a major limitation
being the diffusion of Aβ aggregates, which are gradually, washed
off with successive media changes. Therefore, it is hypothesized
that 3D stem cell models of AD will provide a more compact
and comprehensive brain microenvironment where the local
niche will allow a sufficient Aβ aggregation (D’avanzo et al.,
2015). This theory has been confirmed lately, where 3D matrigel
system has been used for the culture of ReN cells to model
familial AD. The 3D stem cell model of AD showed a significant
deposit of β-amyloid plaques in a 6 week differentiated culture.
The cells further showed elevated levels of phosphorylated tau
protein thereby confirming that 3D based stem cell models
are more efficient in recapitulating the disease pathophysiology
(Choi et al., 2014). A study by Zhang et al. reported the
successful recapitulation of in-vivo like responses in a 3D culture
model of AD. The study comprises neuroepithelial stem cell
derived neuronal culture in a PuraMatrix hydrogel comprising
self assembling peptide matrix and laminin. The study confirmed
that 3D microenvironment allowed Aβ sensing via p21-activated
kinase (Zhang et al., 2014). Genetically engineered hNPCs
production and 3D cell culture protocols for AD modeling have
been standardized and published (Kim et al., 2015).
FIGURE 2 | The landmark studies/discoveries (5 each) related to the major neurodegenerative disorders and the possible role of stem cells in a time
oriented manner.
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It is well reported that mouse iPSCs and ESCs show a better
dopaminergic differentiation potential in a three dimensional
peptide derived nanofibre scaffold. The 3D culture provides a
better environment for the development of the DA neurons
which showed appropriate action potential firing and expressed
the specific markers as well (Ni et al., 2013). Successful
differentiation of chorion derived MSCs into motor neurons has
been recently reported in 3D nanofibrous gelatin scaffold. These
motor neurons shall provide a possibility to model ALS in a
three dimensional scenario (Faghihi et al., 2016). Figure 2 depicts
the landmark studies/discoveries (5 each) related to the major
neurodegenerative disorders and the possible role of stem cells
in a time oriented manner.
CONCLUDING REMARKS
The above discussion so far clearly sheds light on the
widespread applicability of stem cells and induced pluripotent
stem cells in the field of neurodegeneration. Disease modeling,
transplantation therapy, restoration of lost brain functionality
due to injury and aging and regenerative therapeutics are some
of the areas where stem cells have been abundantly used. The
article highlights the advances made especially in the past 5
years as envisaging the entire applicability of stem cells in
neurodegenerative medicine is beyond the scope of the present
discussion. Human stem cells and patient derived iPSCs have
been instrumental in overcoming the major limitations of animal
based research providing a more profound understanding of
the neurodegenerative disorders. Patient derived iPSCs are even
better models for understanding the disease pathophysiology
and mechanistics because they carry the patient’s genotype, bear
the disease mutations and also account for the environmental
influences. Stem cells have also been employed as simplistic
in-vitro tools for screening of therapeutics and drugs. Three
dimensional stem cell based studies and stem cell derived
organoids have further contributed by providing a more in-vivo
like microenvironment which is the closest possible mimic of
a live animal. With technological advancements and efficient
imaging techniques have revolutionized the concept of 3D
stem cell based organoid research. Pharmacological intervention
utilizing natural agents like curcumin has shown neuroprotective
efficacy in clinical and experimental models of neurotoxicity and
can provide beneficial effects in the neurodegenerative disorders
in future (Srivastava et al., 2014). However, the current prevalent
pharmacological treatments provide symptomatic relief only
for a limited period of time and the drugs administered may
have side effects. The advent of stem cell therapy has laid the
foundation keystone for a possible cure with minimized side
effects. Personalized medical treatment using iPSCs is the current
face of modern medicine and constant efforts are being made to
scale down the cost and increase the efficacy of the approach.
Animal based clinical field trials cannot be completely surpassed
and transplantation therapies will require validation. However, if
cells of human origin are employed for the preliminary disease
modeling and therapeutic screening, a lot shall be saved in
FIGURE 3 | The diagrammatic illustration of possible therapeutic
strategies against the prevalent neurodegenerative disorders (ND). The
nature of ND is progressive in nature and limits the clinical utility of
pharmacological drugs which provide only symptomatic relief. Stem cell
therapy and iPSC technology could harness neurorestorative and neuro
regenerative relief for the patients suffering from neurodegenerative disorders
as well as pave way for a possible cure in future.
terms of funds, resource, time and even animal lives. It would
not be an exaggeration to say that with the proficient and
judicious use of stem cells and iPSCs lesser animals shall be
sacrificed and the rate of clinical trial failure shall be curbed.
This shall lessen the moral as well as the economic burden. We
still hope that future research will come up with effective cures
for the fatal neurodegenerative disorders, until then efficient
and affordable disease management and treatment can ensure
a longer and healthier life for the aging population. Figure 3
is a diagrammatic illustration of possible therapeutic strategies
against the prevalent neurodegenerative disorders (ND). The
nature of ND is progressive in nature and limits the clinical
utility of pharmacological drugs which provide only symptomatic
relief. Stem cell therapy and iPSC technology could harness
neurorestorative and neuro regenerative relief for the patients
suffering from neurodegenerative disorders as well as pave way
for a possible cure in future.
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